At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 216 enrolled
Drug / intervention
Epoetin alfadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
In Brief
A Phase 4 clinical trial evaluating Epoetin alfa for Renal Insufficiency, Chronic and 3 related conditions. Completed, enrolled 216 participants across 37 sites in 2 countries.
Detailed Summary
The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving hemodialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartApr 2015
Primary CompletionApr 2016
Study CompletionMay 2016
TodayJul 2026
First PostedOct 1, 2014
Enrollment StartApr 1, 2015
Primary CompletionApr 27, 2016
Study CompletionMay 25, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.8 years ago
Interventions
Epoetin alfadrug
Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.